Amino Acid Substitutions [a]	Mutagenic Oligodeoxyribonucleotide [b]
S39T K42H	5'-GGAAATCGTGGCT**ACC**TGCGAC**CAT**TGCCAATTGAAAGG-3'
Q44N	5'-CTTGCGACAAATGC**AAC**TTGAAAGGTGAAG-3'
L68E E69P	5'-GGACTCTACTCAT**GAACCG**GGTAAAGTTATCC-3'
L74A	5'-GAGGGTAAAGTTATC**GCG**GTTGCTGTTCACGTG-3'
K156R	5'-ATCGAATCTATGAAC**CGT**GAGCTCAAAAAAATC-3'
E170M	5'-GTACGTGATCAGGCT**ATG**CACCTGAAAACCGCG-3'
Y227I	5'-CCGTGTATAC**ATT**CGTGACTCTAG-3'
D229I S230E	5'-CGTGTATACTACCGT**ATCGAA**AGAGACCCGGTTTGG-3'
D253N	5'-GCTGTTGTTATCCAG**AAC**AACTCTGACATCAAAG-3'
N254D	5'-GTTGTTATCCAGGAC**GAT**TCTGACATCAAAGTG-3'
K258I R262S	5'-CTCTGACATC**ATT**GTGGTACCG**TCT**CGTAAAGCTAAAATC-3'
K211S	5'-GATATCCAGACT**AGC**GAACTGCAGAAACAG-3'
K219S	5'-CAGAAACAGATCACT**AGC**ATCCAGAACTTCCG-3'
Q221S	5'-CACTAAAATC**AGC**AACTTCCGTG-3'

Supplemental Table 1 Mutagenic Primers Used to Prepare Chimeric HIV-1 INs

[a] Amino acid substitutions are based on alignment shown in Supplemental Figure 1. For chimeras that were constructed for altered specificity, amino acid substitutions are based on residues in structurally related positions in ASV. For target DNA residues, (211, 219, and 221) substitutions to Ser were made.

[b] The bolded and underlined bases were changed to introduce news amino acid residues into HIV-1 IN. Only the plus strand sense oligos are shown.